Form 4: Lifecore Biomedical Director Receives Equity Grant

Director Matthew E. Korenberg has been granted 25,907 restricted stock units, increasing his total stake in Lifecore Biomedical to nearly 70,000 shares.

Summary

• Matthew E. Korenberg, a Director at Lifecore Biomedical, Inc., acquired 25,907 restricted stock units (RSUs) on June 4, 2026.
• The RSUs convert into common stock on a 1-for-1 basis upon vesting.
• Following this transaction, the reporting person's total beneficial ownership increased to 69,967 shares of common stock.
• The grant is part of standard director compensation and is scheduled to vest in full in approximately one year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive administrative event that increases insider alignment without signaling a change in company fundamentals.

Positives

• Increased insider ownership by approximately 58.8% from the previous holding level.
• Alignment of director interests with shareholders through equity-based compensation.
• The grant includes a vesting cliff that encourages long-term retention of the director.

Negatives

• The acquisition was a grant rather than an open-market purchase, meaning no personal capital was committed by the director.
• Potential for future dilution when the 25,907 units vest and convert to common shares.

Risks

• Vesting is contingent on the director remaining with the company until at least June 4, 2027.
• The ultimate value of the compensation is subject to market fluctuations of LFCR stock over the next 12 months.

Future Outlook

The director is expected to remain on the board through at least the 2027 annual meeting of stockholders to satisfy the vesting requirements of this equity grant.

Management Comments

• No specific management commentary was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is a standard practice in the biotechnology and CDMO sectors to preserve cash while ensuring board members are incentivized to increase long-term company valuation.

Comparison to Industry Standards

• The grant size is consistent with mid-cap biotechnology board compensation structures.
• Vesting terms of one year or the next annual meeting are standard for non-employee director equity awards.
• Comparable companies like Catalent and West Pharmaceutical Services utilize similar RSU structures for board alignment.

Corporate Governance

Related Party Transactions

• The issuance of 25,907 RSUs to Director Matthew E. Korenberg as part of his compensation package.

Stakeholder Impact

• Shareholders may see minor dilution upon the future vesting of these units.
• The board of directors maintains stability through incentivized retention.

Next Steps

• Vesting of the RSUs on June 4, 2027, or the date of the 2027 annual meeting of stockholders.

Key Dates

Recommendation

This is a routine compensation-related filing that does not provide new information regarding the company's operational performance or strategic direction.

Keywords

Lifecore Biomedical, LFCR, Insider Trading, Form 4, Restricted Stock Units, Director Compensation, Matthew Korenberg